Israel Englander’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Israel Englander’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-26,666	Closed	-$15K	–	7838
2021 Q4	$15K	Hold	26,666	–	–	﹤0.01%	6622
2021 Q3	$19K	Buy	+26,666	New	+$260K	﹤0.01%	6658

Other funds holding EUCR

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

SIA

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Israel Englander's EUCR Position: Q4 2022 in Review

Israel Englander sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q4 2022, closing a stake of 80,000 shares — an estimated $802K sold.

Israel Englander first reported a position in EUCR in Q2 2021 and held it in 6 quarters. The position peaked at $1.14M in Q3 2021. 5 funds tracked by Wall St. Rank hold EUCR as of Q4 2022.

Israel Englander reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Israel Englander sold 80,000 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q4 2022, an estimated $802K.
Israel Englander first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q2 2021 and held it in 6 quarters.
Israel Englander's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $1.14M in Q3 2021.
5 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q4 2022.

Based on Millennium Management's 13F filing for Q4 2022, filed 14 Feb 2023.